Download full-text PDF |
Source |
---|
BMC Cancer
January 2025
Department of Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 116 South Zuodaoquan Road, Wuhan, 430079, China.
Objective: Ondansetron orally soluble pellicle can serve as an alternative option for preventing nausea and vomiting in patients who receive chemotherapy. However, there is a lack of clinical evidence regarding ondansetron. This study aimed to explore the efficacy and safety of ondansetron in patients with malignant tumours who received chemotherapy drugs with a moderate-to-high emetic risk.
View Article and Find Full Text PDFLasers Med Sci
January 2025
Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University, 157th Xi 5 Road, Xi'an, 710004, PR China.
Non-tuberculous mycobacterial skin infection lead to complex and lengthy treatment cycles. Antimicrobial photodynamic therapy (aPDT) is an emerging promising approach for treating infections. This study aims to assess the effects of aPDT using curcumin as a photosensitizer (PS) on non-tuberculous mycobacteria, Mycobacterium abscessus, a subtype that has become common in dermatology in recent years.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Water Science and Engineering, Science and Research Branch, Islamic Azad University, Tehran, Iran.
This study investigated the antimicrobial efficacy of graphene, titanium dioxide nanoparticles (TiO2NPs), and calcium oxide nanoparticles (CaONPs) against various microorganisms in dairy wastewater. The minimum inhibitory concentration (MIC) of graphene was determined to be 41.66 mg/L for Escherichia coli and 33.
View Article and Find Full Text PDFJ Dermatolog Treat
December 2025
Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
Baricitinib, a JAK 1/2 inhibitor, is approved for treating severe alopecia areata (AA). This study aimed to evaluate the long-term effectiveness and safety of baricitinib in a real-world setting over 52 weeks. This multicenter retrospective study included 96 adult patients diagnosed with severe AA from 11 Italian Dermatology Units.
View Article and Find Full Text PDFJ Dermatolog Treat
December 2025
Department of Dermatology, Children's Hospital Affiliated to Kunming Medical University, Kunming, China.
To evaluate the long-term efficacy and safety of secukinumab in pediatric patients with generalized pustular psoriasis (GPP). A retrospective study was conducted from July 2021 to July 2024, including 10 children with GPP. Patients were divided into two age groups: children aged 0-3 years received 75 mg of secukinumab, while those aged 3-12 years received 150 mg.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!